Staphylococcus (staph) pneumonia is characterized by the inflammation of the lungs due to the infection by the bacteria called staphylococcus aureus. With this condition, the patient cannot get adequate amounts of oxygen into the bloodstream and instead, fluid and pus collect in the lungs. Signs to look for in order to consider staph pneumonia treatment include fever, chest pain, difficulty in breathing and coughing of bloody mucous.
Apart from pneumonia, staphylococcus aureus bacteria also cause a host of other body conditions. It is the main cause of skin conditions for instance celluitis and boils. As a result, it has been listed as the most important bacterium in the development of diseases in human beings.
As with other forms of pneumonia, the exposure to this bacterium is almost normal and you will not be aware of this until you get the infection. As such, the development of the disease can be from few days to even years. The staph pneumonia treatment should take into account the duration of the infection. Also consider what might have happened to mucous membranes and the skin to allow for the infection to happen. Probably it is the case of a reduced immune ability of the patient.
If it is a minor infection, staph pneumonia treatment might not be necessary as the disease can heal by itself. However, the situation becomes serious if the infection has gone for long without proper attention or is recurrent. It is would be important to have proper diagnosis to check for the presence of a more serious methicillin resistant staphylococcus aureus (MRSA).
By categorizing pneumonia according to the environment in which it is contracted, community associated pneumonia(CAP), hospital acquired pneumonia(HAP), health-care associated pneumonia(HCAP) and ventilator associated pneumonia(VAP) are the main forms of this disease. Staph pneumonia treatment for all these types has encountered new challenges through the emergence of MRSA. As such this categorization of pneumonia has lost its meaning. This has brought in a newer category referred to as community associated (CAMRSA) which poses new challenges to pneumonia patients in hospitals.
Delays in the administration of staph pneumonia treatment could be blamed for the high mortality rates of CAMRSA patients. Specifically, clinicians have continually been blamed for laxity in diagnosis and administration of the respective antibiotics for the reversal of the infections.
In the staph pneumonia treatment, the trend nowadays has been the administration of Vancomycin. Since this treatment has had mixed success, it has been necessary to develop other solutions for the treatment of CAMRSA. Therefore to add to the antibiotic treatment, controlling toxin production using antistaphylococcal antibodies is also another method. In this case, clindamycin has been suggested as the appropriate remedy but studies are still ongoing on its appropriateness.
There has a significant shift in the clinical presentation of staph pneumonia infections with hitherto unaffected people reporting severe and even fatal pneumonia results. This is attributed to the emergence of methicillin resistant strains of staph pneumonias. With the risk of further infections rife, it is prudent to manage the CAMRSA immediately the diagnosis has been made.
Prevention methods for CAMRSA may not available for the purpose of complimenting staph pneumonia treatment, but there are proofs of the spread of the disease among specific groups. While isolation of patients is thought to be effective, policy restrictions make such a move impossible.
In the recent past, there has been a significant rise in the number of CAMRSA cases some resulting in deaths of victims. For the staph pneumonia treatment to be successful, it is critical for the early recognition of the symptoms. After confirming the presence of the condition from tests, antibiotics should be offered and spread of the infection prevented.